Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2026Journal of the Korean Gastric Cancer AssociationOpen Access

CLDN18.2 in Gastric Cancer: Current Therapeutic Landscape and Future Perspectives

View Full Paper
Ask AI
Bookmark
Share

Authors

FZFei ZhangAnhui Medical UniversityUOUkyo OkazakiNational Cancer Center Hospital EastINI NakayamaNational Cancer Center Hospital East

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Zhang et al. (2026) studied this question.

synapsesocial.com/papers/6a159ac637103a43379ff811https://doi.org/10.5230/jgc.2026.26.e10
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Claudin Proteins in Human Cancer: Promising New Targets for Diagnosis and Therapy2005 · 578 citations
  2. 2claudin-18 , a Novel Downstream Target Gene for the T/EBP/NKX2.1 Homeodomain Transcription Factor, Encodes Lung- and Stomach-Specific Isoforms through Alternative Splicing2001 · 292 citations
  3. 3CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial2025 · 52 citations
  4. 4Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer2020 · 99 citations
  5. 5Phase 1 trial of zolbetuximab in Japanese patients with CLDN18 .2+ gastric or gastroesophageal junction adenocarcinoma2022 · 28 citations